Q3 Earnings Spotlight: Abiomed Shines Among Cardiology Device-Makers
Executive Summary
Reported sales and earnings from the publicly traded cardiovascular device companies show strong performance across the sector, spurred by new approvals and clinical trials, in the quarter that ended Sept. 30. Here's a recap of results from the cardio device companies that have reported so far, including Abbott, Abiomed, and Reva.
You may also be interested in...
Abbott Launches Trial Of First-Of-A-Kind Resorbable Scaffold For Critical Limb Ischemia
The Esprit BTK everolimus-eluting resorbable scaffold is designed to treat arteries below the knee. No stents or drug-coated balloons are currently FDA-approved for that indication.
2018 Global Approvals Analysis: Emerging-Market Regulators And Companies Make Their Presence Felt
The list of medical device approvals outside the US captured by Medtech Insight's Approvals Tracker in 2018 was shorter than in 2017, but it includes approvals from 14 different territories – more than one-fifth of the approvals came from emerging markets – covering more than 50 different indication categories.
Abiomed Touts New Study Results, Potential To Revolutionize Heart-Attack Treatment
Promising new results from a pilot study of Abiomed’s Impella device to reduce damage after myocardial infarction sets the company up to start a pivotal study, which, if successful, could change how patients are treated immediately after an attack.